CureVac B.V. (CVAC) shares plunged 5.14% in Wednesday's trading session, as investors appear to be bracing for the company's upcoming first-quarter earnings report. The steep decline comes amid a broader context of anticipated financial results from various companies in the biotech and pharmaceutical sectors.

According to a recently released earnings calendar, CureVac is scheduled to report its Q1 2025 results soon. Analysts are estimating an earnings per share (EPS) of -$0.21 for the quarter, indicating expected losses for the company. This negative outlook may be contributing to the downward pressure on the stock price as investors adjust their positions ahead of the official announcement.

The significant drop in CureVac's stock price suggests that market participants might be concerned about the company's financial performance or future prospects. As a biopharmaceutical company focused on developing a new class of transformative medicines, CureVac's earnings report will likely be closely scrutinized for insights into its ongoing research and development efforts, cash burn rate, and progress in its product pipeline. Investors will be keen to hear any updates on the company's mRNA technology platform and its potential applications in vaccines and therapeutics.